Interleukin 4 inhibition as a potential therapeutic in pemphigus

Cytokine

Volumn 77, Issue , 2016, Pages 189-195

  Tavakolpour, Soheil ^a   Tavakolpour, Vahid ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b STEM CELL TECHNOLOGY RESEARCH CENTER   (Iran)

Author keywords

Anti cytokine therapy; Autoimmune disease; Interleukin 4; Pemphigus

Indexed keywords

ACETYLSALICYLIC ACID; DESMOGLEIN 1; DESMOGLEIN 3; DUPILUMAB; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INTERLEUKIN 4; RITUXIMAB; IL4 PROTEIN, HUMAN; IMMUNOGLOBULIN G; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; HUMAN; PATHOGENESIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REMISSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL DIFFERENTIATION; DRUG EFFECTS; GENE REARRANGEMENT; IMMUNOLOGY; METABOLISM; TH2 CELL;

ANTIBODIES, MONOCLONAL; CELL DIFFERENTIATION; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; INTERLEUKIN-4; MODELS, IMMUNOLOGICAL; PEMPHIGUS; RECEPTORS, INTERLEUKIN-4; TH2 CELLS;

EID: 84949105952     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.09.017     Document Type: Article

References (106)

1. Luckheeram R.V., Zhou R., Verma A.D., Xia B. CD4+T cells: differentiation and functions. Clin. Dev. Immunol. 2012, 2012:12.
2. Sun B. T Helper Cell Differentiation and Their Function 2014, Springer.
3. Liao W., Schones D.E., Oh J., Cui Y., Cui K., Roh T.-Y., et al. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor α-chain expression. Nat. Immunol. 2008, 9:1288-1296.
4. Gilmour J., Lavender P. Control of IL-4 expression in T helper 1 and 2 cells. Immunology 2008, 124:437-444.
5. Chen Z., Lund R., Aittokallio T., Kosonen M., Nevalainen O., Lahesmaa R. Identification of novel IL-4/Stat6-regulated genes in T lymphocytes. J. Immunol. 2003, 171:3627-3635.
6. J.D. Farrar, H. Asnagli, K.M. Murphy, T helper subset development: roles of instruction, selection, and transcription, 2002.
7. Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007, 13:139-145.
8. Biedermann T., Röcken M. Pro-and anti-inflammatory effects of IL-4: from studies in mice to therapy of autoimmune diseases in humans. Animal Models of T Cell-Mediated Skin Diseases 2005, 235-242. Springer.
9. Swain S.L., Weinberg A.D., English M., Huston G. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 1990, 145:3796-3806.
10. Le Gros G., Ben-Sasson S.Z., Seder R., Finkelman F., Paul W. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J. Exp. Med. 1990, 172:921-929.
11. Hsieh C.-S., Heimberger A.B., Gold J.S., O'Garra A., Murphy K.M. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc. Natl. Acad. Sci. 1992, 89:6065-6069.
12. Seder R.A., Paul W.E., Davis M.M., de St Groth B.F. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J. Exp. Med. 1992, 176:1091-1098.
13. Seder R.A. Acquisition of lymphokine-producing phenotype by CD4+ T cells. J. Allergy Clin. Immunol. 1994, 94:1195-1202.
14. Vijayanand P., Seumois G., Simpson L.J., Abdul-Wajid S., Baumjohann D., Panduro M., et al. Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity 2012, 36:175-187.
15. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 2003, 8:223-246.
16. Giordano C.N., Sinha A.A. Cytokine networks in Pemphigus vulgaris: an integrated viewpoint. Autoimmunity 2012, 45:427-439.
17. Hertl M. Autoimmune Diseases of the Skin: Pathogenesis, Diagnosis, Management 2011, Springer Science & Business Media.
18. Uzun S., Durdu M., Akman A., Gunasti S., Uslular C., Memisoglu H.R., et al. Pemphigus in the Mediterranean region of Turkey: a study of 148 cases. Int. J. Dermatol. 2006, 45:523-528.
19. Chams-Davatchi C., Valikhani M., Daneshpazhooh M., Esmaili N., Balighi K., Hallaji Z., et al. Pemphigus: analysis of 1209 cases. Int. J. Dermatol. 2005, 44:470-476.
20. Yazdanfar A. Epidemiology of pemphigus in Hamedan (west of Iran): a 10 year retrospective study (1995-2004). Int. J. Pharm. 2010, 1:157-160.
21. Micali M., Musumeci M., Maria L., Nasca M., Rita M. Epidemiologic analysis and clinical course of 84 consecutive cases of pemphigus in eastern Sicily. Int. J. Dermatol. 1998, 37:197-200.
22. Krain L.S. Pemphigus: epidemiologic and survival characteristics of 59 patients, 1955-1973. Arch. Dermatol. 1974, 110:862-865.
23. Aboobaker J., Morar N., Ramdial P.K., Hammond M.G. Pemphigus in South Africa. Int. J. Dermatol. 2001, 40:115-119.
24. Amagai M., Tsunoda K., Zillikens D., Nagai T., Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J. Am. Acad. Dermatol. 1999, 40:167-170.
25. Amagai M., Klaus-Kovtun V., Stanley J.R. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991, 67:869-877.
26. Koga H., Ohyama B., Tsuruta D., Ishii N., Hamada T., Dainichi T., et al. Five Japanese cases of antidesmoglein 1 antibody-positive and antidesmoglein 3 antibody-negative pemphigus with oral lesions. Br. J. Dermatol. 2012, 166:976-980.
27. Wang J., Kwon J., Ding X., Fairley J.A., Woodley D.T., Chan L.S. Nonsecretory IgA1 autoantibodies targeting desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis. Am. J. Pathol. 1997, 150:1901.
28. Hashimoto T., Ebihara T., Nishikawa T. Studies of autoantigens recognized by IgA anti-keratinocyte cell surface antibodies. J. Dermatol. Sci. 1996, 12:10-17.
29. Futei Y., Amagai M., Ishii K., Kuroda-Kinoshita K., Ohya K., Nishikawa T. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J. Dermatol. Sci. 2001, 26:55-61.
30. Funakoshi T., Lunardon L., Ellebrecht C., Nagler A., O'Leary C., Payne A. Enrichment of total serum IgG4 in patients with pemphigus. Br. J. Dermatol. 2012, 167:1245-1253.
31. Warren S., Arteaga L., Rivitti E., Aoki V., Hans-Filho G., Qaqish B., et al. The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus. J. Invest. Dermatol. 2003, 120:1-5.
32. Bhol K., Mohimen A., Ahmed A. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994, 189:85-89.
33. Green M.G., Bystryn J.-C. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch. Dermatol. 2008, 144:1621-1624.
34. Dhandha M.M., Seiffert-Sinha K., Sinha A.A. Specific immunoglobulin isotypes correlate with disease activity, morphology, duration and HLA association in Pemphigus vulgaris. Autoimmunity 2012, 45:516-526.
35. Zhu H., Chen Y., Zhou Y., Wang Y., Zheng J., Pan M. Cognate Th2-B cell interaction is essential for the autoantibody production in pemphigus vulgaris. J. Clin. Immunol. 2012, 32:114-123.
36. Veldman C.M., Gebhard K.L., Uter W., Wassmuth R., Grötzinger J., Schultz E., et al. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J. Immunol. 2004, 172:3883-3892.
37. Rizzo C., Fotino M., Zhang Y., Chow S., Spizuoco A., Sinha A. Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease. Clin. Exp. Dermatol. 2005, 30:535-540.
38. Akdis C.A., Blesken T., Akdis M., Wüthrich B., Blaser K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest. 1998, 102:98.
39. Satoguina J.S., Weyand E., Larbi J., Hoerauf A. T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J. Immunol. 2005, 174:4718-4726.
40. Jeannin P., Lecoanet S., Delneste Y., Gauchat J.-F., Bonnefoy J.-Y. IgE versus IgG4 production can be differentially regulated by IL-10. J. Immunol. 1998, 160:3555-3561.
41. Snapper C., Finkelman F., Paul W. Differential regulation of IgG1 and IgE synthesis by interleukin 4. J. Exp. Med. 1988, 167:183-196.
42. Snapper C.M., Finkelman F.D., Paul W.E. Regulation of IgG1 and IgE production by interleukin 4. Immunol. Rev. 1988, 102:51-75.
43. Lebman D.A., Coffman R.L. Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures. J. Exp. Med. 1988, 168:853-862.
44. Gascan H., Gauchat J.-F., Roncarolo M.-G., Yssel H., Spits H., de Vries J.E. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J. Exp. Med. 1991, 173:747-750.
45. Ishizaka A., Sakiyama Y., Nakanishi M., Tomizawa K., Oshika E., Kojima K., et al. The inductive effect of interleukin-4 on IgG4 and IgE synthesis in human peripheral blood lymphocytes. Clin. Exp. Immunol. 1990, 79:392-396.
46. Satyam A., Khandpur S., Sharma V., Sharma A. Involvement of TH1/TH2 cytokines in the pathogenesis of autoimmune skin disease-pemphigus vulgaris. Immunol. Invest. 2009, 38:498-509.
47. Caproni M., Giomi B., Cardinali C., Salvatore E., Pestelli E., D'Agata A., et al. Further support for a role for Th2-like cytokines in blister formation of pemphigus. Clin. Immunol. 2001, 98:264-271.
48. Lin M.-S., Swartz S.J., Lopez A., Ding X., Fernandez-Vina M.A., Stastny P., et al. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J. Clin. Invest. 1997, 99:31.
49. Eid H., El-Gamal B. Cytokine profiles in the sera of Egyptian patients with oral pemphigus vulgaris. Braz. J. Oral Sci. 2011, 10:83-87.
50. H. Mortazavi, A. Amirzargar, M. Valikhani, Z. Halaji, P.M. Danesh, T.M. Nazemi, et al., The Influence of Treatment of Pemphigus Vulgarison the Serum Level of Cytokines, 2008.
51. Zeoti D., Figueiredo J., Chiossi M., Roselino A. Serum cytokines in patients with Brazilian pemphigus foliaceus (fogo selvagem). Braz. J. Med. Biol. Res. 2000, 33:1065-1068.
52. Rico M., Benning C., Weingart E., Streilein R., Hali R. Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris. Br. J. Dermatol. 1999, 140:1079-1086.
53. Akdis M., Burgler S., Crameri R., Eiwegger T., Fujita H., Gomez E., et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J. Allergy Clin. Immunol. 2011, 127. 701-721.e70.
54. Kondo M., Takeshita T., Ishii N., Nakamura M., Watanabe S., K-i Arai., et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science 1993, 262:1874-1877.
55. Russell S.M., Keegan A.D., Harada N., Nakamura Y., Noguchi M., Leland P., et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science 1993, 262:1880-1883.
56. Lin J.-X., Migone T.-S., Tseng M., Friedmann M., Weatherbee J.A., Zhou L., et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995, 2:331-339.
57. Dickensheets H.L., Donnelly R.P. Inhibition of IL-4-inducible gene expression in human monocytes by type I and type II interferons. J. Leukoc. Biol. 1999, 65:307-312.
58. Zamorano J., Rivas M., Perez G. Interleukin-4: a multifunctional cytokine. Immunologia 2003, 22:215-224.
59. Zhou M., Ouyang W. The function role of GATA-3 in Th1 and Th2 differentiation. Immunol. Res. 2003, 28:25-37.
60. Ho I.-C., Lo D., Glimcher L.H. C-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and-independent mechanisms. J. Exp. Med. 1998, 188:1859-1866.
61. Sykes L., MacIntyre D.A., Yap X.J., Ponnampalam S., Teoh T.G., Bennett P.R. Changes in the Th1: Th2 cytokine bias in pregnancy and the effects of the anti-inflammatory cyclopentenone prostaglandin 15-deoxy-prostaglandin. Mediators Inflamm. 2012, 2012.
62. Sykes L., MacIntyre D.A., Yap X.J., Teoh T.G., Bennett P.R. The Th1: th2 dichotomy of pregnancy and preterm labour. Mediators Inflamm. 2012, 2012.
63. Kardos M., Levine D., Gürcan H.M., Ahmed A.R. Pemphigus vulgaris in pregnancy: analysis of current data on the management and outcomes. Obstet. Gynecol. Surv. 2009, 64:739-749.
64. Daneshpazhooh M., Chams-Davatchi C., Valikhani M., Aghabagheri A., Mortazavizadeh S., Barzegari M., et al. Pemphigus and pregnancy: a 23-year experience. Indian J. Dermatol., Venereol., Leprol. 2011, 77:534.
65. Action IPAI-LAIPAI-L, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093327.htm.
66. Information on Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade E, Humira, Cimzia, and Simponi) (Information on Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi)), http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109340.htm.
67. Clark D.N., Markham J.L., Sloan C.S., Poole B.D. Cytokine inhibition as a strategy for treating systemic lupus erythematosus. Clin. Immunol. 2013, 148:335-343.
68. Hall R., Fairley J., Woodley D., Werth V., Hannah D., Streilein R., et al. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br. J. Dermatol. 2015, 172:760-768.
69. Sinha A. To (anti-) TNF or not (anti-) TNF? That is the question in pemphigus. Br. J. Dermatol. 2015, 172:564-565.
70. José Antonio Delgado García, Carmen Pérez Robles, Juan José Mata Molanes, Laura Moreno Narro, Paula Arana Berganza, Level of IgG4 anti-desmoglein 3 antibodies correlates with disease activity in patients with pemphigus vulgaris, Autoimmun Infec. Dis. 1.1 (2005). doi:10.16966/aidoa.101.
71. Grazia Roncarolo M., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 2006, 212:28-50.
72. Cianferoni A., Schroeder J.T., Kim J., Schmidt J.W., Lichtenstein L.M., Georas S.N., et al. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001, 97:1742-1749.
73. Hsia J., Sarin N., Oliver J.H., Goldstein A.L. Aspirin and thymosin increase interleukin-2 and interferon-γ production by human peripheral blood lymphocytes. Immunopharmacology 1989, 17:167-173.
74. Perez-G M., Melo M., Keegan A.D., Zamorano J. Aspirin and salicylates inhibit the IL-4-and IL-13-induced activation of STAT6. J. Immunol. 2002, 168:1428-1434.
75. Spiegelberg H., Falkoff R., O'Connor R., Beck L. Interleukin-2 inhibits the interleukin-4-induced human IgE and IgG4 secretion in vivo. Clin. Exp. Immunol. 1991, 84:400.
76. El-Darouti M.A., Hegazy R.A., Hay R.M.A., El Hawary M.S., Tawdy A.M., Fawzy M.M., et al. Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial. Arch. Dermatol. Res. 2015, 307:299-307.
77. Berger A. Th1 and Th2 responses: what are they?. BMJ 2000, 321:424.
78. Beck L.A., Thaçi D., Hamilton J.D., Graham N.M., Bieber T., Rocklin R., et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 2014, 371:130-139.
79. Hamilton J.D., Suárez-Fariñas M., Dhingra N., Cardinale I., Li X., Kostic A., et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J. Allergy Clin. Immunol. 2014, 134:1293-1300.
80. Runge M.S., Patterson C. Principles of Molecular Medicine 2007, Springer Science & Business Media.
81. Vatrella A., Fabozzi I., Calabrese C., Maselli R., Pelaia G. Dupilumab: a novel treatment for asthma. J. Asthma Allergy 2013, 7:123-130.
82. Lim S.H., Beers S.A., French R.R., Johnson P.W., Glennie M.J., Cragg M.S. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010, 95:135-143.
83. Thatayatikom A., White A.J. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun. Rev. 2006, 5:18-24.
84. Willems M., Haddad E., Niaudet P., Kone-Paut I., Bensman A., Cochat P., et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J. Pediatr. 2006, 148. 623-627.e3.
85. Dass S., Rawstron A.C., Vital E.M., Henshaw K., McGonagle D., Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008, 58:2993-2999.
86. Morrison L.H. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J. Am. Acad. Dermatol. 2004, 51:817-819.
87. Fernando S.L., O'Connor K.S. Treatment of severe pemphigus foliaceus with rituximab. Med. J. Aust. 2008, 189:289-290.
88. M. Alter, M. Wittmann, B. Völker, A. Kapp, T. Werfel, R. Gutzmer, Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 60 (2009) 743-748.
89. Xu R.-C., Zhu H.-Q., Li W.-P., Zhao X.-Q., Yuan H.-J., Zheng J., et al. The imbalance of Th17 and regulatory T cells in pemphigus patients. Eur. J. Dermatol. 2013, 23:795-802.
90. K. Shimoda, J. van Deursent, M.Y. Sangster, S.R. Sarawar, R.T. Carson, R.A. Tripp, et al., Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene, 1996.
91. K. Takeda, T. Tanaka, W. Shi, M. Matsumoto, M. Minami, S.-I. Kashiwamura, et al., Essential role of Stat6 in IL-4 signalling, 1996.
92. Kaplan M.H., Schindler U., Smiley S.T., Grusby M.J. Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity 1996, 4:313-319.
93. Kurata H., Lee H.J., O'Garra A., Arai N. Ectopic expression of activated Stat6 induces the expression of Th2-specific cytokines and transcription factors in developing Th1 cells. Immunity 1999, 11:677-688.
94. Jacobson N.G., Szabo S.J., Weber-Nordt R.M., Zhong Z., Schreiber R.D., Darnell J., et al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat) 3 and Stat4. J. Exp. Med. 1995, 181:1755-1762.
95. W.E. Thierfelder, J.M. van Deursen, K. Yamamoto, R.A. Tripp, S.R. Sarawar, R.T. Carson, et al., Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells, 1996.
96. Grusby M.J. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996, 382:11.
97. Powrie F., Menon S., Coffman R.L. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol. 1993, 23:2223-2229.
98. Oriss T.B., McCarthy S.A., Morel B.F., Campana M., Morel P.A. Crossregulation between T helper cell (Th) 1 and Th2: inhibition of Th2 proliferation by IFN-gamma involves interference with IL-1. J. Immunol. 1997, 158:3666-3672.
99. Hertl M., Veldman C. Pemphigus-paradigm of autoantibody-mediated autoimmunity. Skin Pharmacol. Physiol. 2001, 14:408-418.
100. Ahmed A.R., Spigelman Z., Cavacini L.A., Posner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 2006, 355:1772-1779.
101. Aikawa N.E., de Carvalho J.F., Silva C.A.A., Bonfá E. Immunogenicity of anti-TNF-α agents in autoimmune diseases. Clin. Rev. Allergy Immunol. 2010, 38:82-89.
102. Chatzantoni K., Mouzaki A. Anti-TNF-α antibody therapies in autoimmune diseases. Curr. Top. Med. Chem. 2006, 6:1707-1714.
103. Astrakhantseva I., Efimov G., Drutskaya M., Kruglov A., Nedospasov S. Modern anti-cytokine therapy of autoimmune diseases. Biochemistry (Moscow) 2014, 79:1308-1321.
104. Afshari J.T., Hosseini R.F., Farahabadi S.H., Heydarian F., Boskabady M.H., Khoshnavaz R., et al. Association of the expression of IL-4 and IL-13 genes, IL-4 and IgE serum levels with allergic asthma. Iran. J. Allergy, Asthma Immunol. 2007, 6:69-72.
105. Lee Y.C., Lee K.H., Lee H.B., Rhee Y.K. Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-γ in acute asthma. J. Asthma 2001, 38:665-671.
106. Miller R.L., Eppinger T.M., McConnell D., Cunningham-Rundles C., Rothman P. Analysis of cytokine signaling in patients with extrinsic asthma and hyperimmunoglobulin E. J. Allergy Clin. Immunol. 1998, 102:503-511.